Table 1.
A sub-set of our proteomics data.
| Locus (LVS, S4) | Protein (MW-kDa) | Spectral counts | Fold changes | VF | FevR regulon | Times reports as an antigen | |||
|---|---|---|---|---|---|---|---|---|---|
| % Sol. | Abundance Rank MHB, BHI | BHI/MHB | BHI/BCA | MΦ/BCA, Bent, 4 h, 8 h | |||||
| 1,191, 1,269 | DnaK (69) | 93 | 3, 3 | 0.7 ± 0.1 | 1.2 ± 0.1 | 1.0, 0.9 | Y | 7 | |
| 1,714, 1,696 | GroE (57) | 96 | 1, 1 | 1.2 ± 0.0 | 1.2 ± 0.0 | 0.5, 0.6 | Y | 8 | |
| 1,751, 137 | EFTu (43) | 92 | 4, 4 | 0.8 ± 0.2 | 0.6 ± 0.1 | 1.0, 0.5 | 5 | ||
| 1,328, 583 | FopA (41) | 16 | 31, 59 | 0.8 ± 0.2 | 0.8 ± 0.1 | 1.7, 1.5 | Y | 6 | |
| FPI PROTEINS | |||||||||
| 126, 1,699 | PdpA (95) | 92 | 263, 24 | 4.8 ± 1.1 | 1.8 ± 0.1 | 3.2, 6.9 | Y | Y | 0 |
| 125, 1,700 | PdpB (125) | 35 | 175, 26 | 6.6 ± 5.4 | 1.9 ± 0.0 | 1.9, 4.9 | Y | 0 | |
| 124, 1,701 | IglE (14) | 0 | 955, 772 | 3.7 | 2.7 ± 1.3 | 2.0, 6.2 | Y | 0 | |
| 123, 1,702 | VgrG (18) | 99 | 546, 224 | 6.6 ± 2.1 | 2.3 ± 1.0 | 4.3, 8.1 | Y | 0 | |
| 122, 1,703 | IglF (65) | 80 | 868, 435 | 11.9 ± 13 | 0.1 ± 0.2 | 2.4, 6.3 | Y | Y | 0 |
| 121, 1,704 | IglG (18) | – | ND, 910 | ND | 0.7 ± 1.0 | 3.0, 6.1 | Y | 0 | |
| 120, 1,705 | IglH (55) | 91 | 400, 95 | 6.5 ± 3.6 | 1.9 ± 0.9 | 2.5, 4.4 | Y | Y | 0 |
| 119, 1,706 | DotU (25) | 61 | 487, 308 | 3.7 ± 2.3 | 1.0 ± 0.9 | 2.2, 2.9 | Y | Y | 0 |
| 118, 1,707 | IglI (45) | 81 | 305, 57 | 5.4 ± 2.1 | 2.8 ± 0.5 | 2.0, 3.0 | Y | Y | 0 |
| 117, 1,708 | IglJ (30) | 87 | 914, 501 | 5.2 ± 2.4 | 2.3 ± 0.4 | 1.7, 3.0 | Y | Y | 1 |
| 116, 1,709 | PdpC (156) | 80 | 117, 7 | 6.3 ± 3.9 | 2.8 ± 0.3 | 0.9, 2.2 | Y | Y | 0 |
| 115, 1,710 | Hcp (22) | 82 | 971, 489 | 8.2 ± 3.9 | 2.0 ± 0.6 | 1.5, 2.4 | 0 | ||
| 114, 1,711 | IglD (46) | 90 | 328, 117 | 4.8 ± 0.8 | 1.3 ± 0.0 | 1.7, 4.0 | Y | Y | 0 |
| 113, 1,712 | IglC (23) | 96 | 59, 19 | 4.0 ± 0.4 | 4.0 ± 1.8 | 2.0, 5.4 | Y | Y | 2 |
| 112, 1,713 | IglB (55) | 82 | 23, 6 | 4.0 ± 1.0 | 1.7 ± 0.2 | 2.1, 3.7 | Y | Y | 2 |
| 111, 1,714 | IglA (21) | 83 | 310, 61 | 4.4 ± 1.4 | 1.8 ± 0.3 | 2.5, 4.3 | Y | Y | 0 |
| NA, 1,715 | PdpD, NA | ND | ND | ND | ND | NA | Y | 0 | |
| FPI protein average* | 5.3 | 2.2 | 2.2, 4.6 | ||||||
| KNOWN FPI REGULATORS | |||||||||
| 449, 383 | FevR (13) | 83 | 951, 655 | 5.0 ± 0.3 | 2.6 ± 1.8 | 3.2, 6.9 | Y | Y | 0 |
| 552, 1,557 | PmrA (26) | 99 | 144, 175 | 2.0 ± 0.9 | 0.8 ± 0.1 | 0.6, 0.8 | Y | Y | 0 |
| 1,606, 458 | SspA (24) | 92 | 417, 399 | 0.8 ± 0.2 | 1.3 ± 0.1 | 0.6, 1.2 | Y | 0 | |
| 1,185, 1,275 | MglA (22) | 100 | 522, 654 | 0.6 ± 0.3 | 0.9 ± 0.1 | 1.9, 0.4 | Y | 0 | |
| 1,184, 1,276 | MglB (15) | - | 836, 963 | ND | ND | 1.6, 0.8 | Y | 0 | |
| NON-FPI MARKERS of GROWTH HISTORY | |||||||||
| 1,503, 720 | Dgt (50) | 100 | 599, 360 | 5.2 ± 0.3 | 1.7 ± 0.1 | 3.2, 5.3 | 0 | ||
| 673, 1,390 | PanC (30) | 95 | 492, 225 | 4.1 ± 0.7 | 1.4 ± 0.3 | 1.0, 1.1 | Y | 0 | |
| 675, 1,388 | PanG (27) | 88 | 743, 317 | 3.5 ± 0.7 | 0.7 + 0.4 | 1.8, 2.9 | Y | 0 | |
| 207, 296 | Pcp (24) | 91 | 315, 178 | 3.0 ± 1.1 | 1.7 ± 0.1 | 4.3, 5.2 | Y | Y | 0 |
| 1,832, 29 | FslA (74) | 74 | 643, 295 | 5.5 ± 4.8 | 2.4 ± 0.3 | 3.0, 5.9 | Y | Y | 0 |
| 1,834, 27 | FslC (47) | 89 | 856, 333 | 7.5 ± 3.1 | 0.9 ± 0.2 | 2.2, 3.4 | Y | 0 | |
| 78, 1671 | RibD (40) | 100 | 449, 792 | 0.43 ± 0.0 | 0.11 ± 0.0 | 1.1, 1.0 | <s/> | 0 | |
| 1,739, 149 | MetK (42) | 91 | 212, 542 | 0.35 ± 0.0 | 0.54 ± 0.2 | 0.6, 0.5 | 0 | ||
| 1,478, 1,317 | GuaB (52) | 100 | 12, 55 | 0.35 ± 0.0 | 0.37 ± 0.2 | 0.3, 0.7 | Y | 1 | |
| LPS/CAPSULE ENZYMES | |||||||||
| 606, 1,450 | WbtM (39) | 100 | 334, 300 | 2.1 ± 0.3 | 0.7 ± 0.1 | 0.9, 1.6 | Y | Y | 0 |
| 600, 1,456 | WbtH (72) | 67 | 247, 242 | 1.7 ± 0.0 | 0.9 ± 0.3 | 0.3, 0.3 | 0 | ||
| 596, 1,460 | WbtE (49) | 98 | 74, 64 | 1.5 ± 0.1 | 1.0 ± 0.2 | 0.5, 0.5 | Y | 0 | |
| 595, 1,461 | WbtD (42) | 94 | 476, 402 | 1.5 ± 0.2 | 0.6 ± 0.3 | 0.5, 0.5 | Y | Y | 0 |
| 1,399, 1,478 | KdsB (28) | 93 | 276, 238 | 1.8 ± 0.4 | 1.0 ± 0.0 | 1.2, 2.2 | 0 | ||
| 609, 1,447 | ManB (55) | 100 | 558, 585 | 1.6 ± 0.2 | 0.6 ± 0.6 | 0.8, 0.9 | Y | 0 | |
| RIBOSOMAL PROTEINS | |||||||||
| 47 ribosomal proteins for which we have matched data | 24 down | 8 down | 12 down, 32 down | ||||||
FTL (LVS) and FTT (S4) locus numbers are indicated along with the proteins name and mass predicted from the LVS genome. Data based upon label-free spectral counts include solubility [the percentage of each protein's total tryptic peptides detected in either the soluble (S) or membrane (M) fractions] and abundance rank for each protein in MHB-Ft and BHI-Ft. Fold change data is based on reciprocal 16O and 18O labeling performed in biological duplicate to yield the indicated mean and standard deviations. Numerical data in bold font represent statistically significant changes [for each protein the status as a virulence factor (VF) was drawn from (Baron and Nano, 1998; Lai et al., 2001; Santic et al., 2005; Brotcke et al., 2006; Maier et al., 2006; Tempel et al., 2006; Maier et al., 2007; Santic et al., 2007; Su et al., 2007; Thomas et al., 2007; Bonquist et al., 2008; Sammons-Jackson et al., 2008; Barker et al., 2009; Buchan et al., 2009; Dean et al., 2009; Schmerk et al., 2009; Ahlund et al., 2010; McCaffrey et al., 2010; Broms et al., 2011, 2012a; Straskova et al., 2012; Robertson et al., 2013, 2014; Rasmussen et al., 2015)]; status as a FevR regulon member was drawn from Charity et al. (2007, 2009), Brotcke and Monack (2008), and Ramsey et al. (2015); the number of times each protein has been reported as a target of infection-derived Ab was drawn from references (Twine et al., 2006b, 2010, 2012a; Janovska et al., 2007; Sundaresh et al., 2007; Savitt et al., 2009; Fulton et al., 2011; Nuti et al., 2011; Golovliov et al., 2013; Chu et al., 2014), and the transcriptional fold changes upon intracellular growth for 4 and 8 h were drawn from Bent et al. (2013).
Excludes values for IglF.